Palliative radiation treatment of cutaneous mycosis fungoides—A dose response

Mycosis fungoides involving the oral cavity

“…Mycosis fungoides is a radiosensitive disease. Cotter et al described a dose–response relationship with doses in the range of 30–40 Gy in standard fractionation providing excellent local control for cutaneous disease with the avoidance of repetitive treatments 25 . This radiosensitivity is reflected in the present case with complete regression of both lesions; however, the normal tissue loss as a result of tumour regression in the left pinna is somewhat unusual and unexpected.…”

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

“…90 Superficial irradiation of specific lesions achieves a CR in more than 90% of treated tumours. 46 TSEB has also been combined with total nodal irradiation. Micaily and colleagues reported that this procedure resulted in 100% CRs in 14 patients with stage I-II disease, including 5 with stage IIB disease.…”

Complete Remission of Previously Intractable Peripheral Cutaneous T-Cell Lymphoma of the Lower Extremity Using Isolated Hyperthermic Limb Perfusion with Melphalan (1-Phenylalanine Mustard)

“…To our knowledge there have been no known clinical trials for the treatment of this group of PCTCL, as they are heterogeneous and infrequent. These include topical chemotherapy with agents like carmustine (BCNU) and nitrogen mustard (NM), [11] light psoralen ultraviolet (PUVA) therapy, [12] local [13] and generalized [14] superficial ionizing radiation, interferon therapy, [15] extracorporeal photochemotherapy also known as photopheresis, [16] retinoids, [17] monoclonal antibodies, [18] DABIL-2 toxin, [19] and systemic chemotherapy. [3] The most important clinical prognostic variables in patients with cutaneous T-cell lymphomas are the type of lesion and the percent of total skin surface involved, the nodal status, the visceral involvement, and the presence of lymphoma cells in the circulation.…”